Second‐line treatment for acute graft‐versus‐host disease with mesenchymal stromal cells: A decision model
Frederick W. Thielen(University Medical Center Freiburg), Carin A. Uyl‐de Groot(Erasmus University Rotterdam), Franco Locatelli(Bambino Gesù Children's Hospital), Alba Redondo(Complejo Hospitalario de Salamanca), Jaap Jan Zwaginga(Leiden University Medical Center), Friso Calkoen(Princess Máxima Center), Liesbeth E.M. Oosten(Leiden University Medical Center), Fermín Sánchez‐Guijo(Universidad de Salamanca), Arjan C. Lankester(Leiden University Medical Center), Katarina Le Blanc(Karolinska University Hospital), Hedwig M. Blommestein(Erasmus University Rotterdam), W.E. Fibbe(Leiden University Medical Center), Mattia Algeri(Bambino Gesù Children's Hospital)
Cited by 6
Related Papers
Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study
|The Lancet Respiratory Medicine|2020|738
Human Bone Marrow–Derived Mesenchymal Stem Cells Do Not Undergo Transformation after Long-term<i>In vitro</i>Culture and Do Not Exhibit Telomere Maintenance Mechanisms
|Cancer Research|2007|702
Immunobiology of Human Mesenchymal Stem Cells and Future Use in Hematopoietic Stem Cell Transplantation
|Biology of Blood and Marrow Transplantation|2005|481
Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation
|New England Journal of Medicine|2020|418